Amgen's BiTE for lung cancer backed for EU approval Amgen's fast-growing bispecific T-cell engager Imdylltra should be cleared as a second-line therapy for small cell lung cancer, said the CHMP

#Amgen's fast-growing bispecific T-cell engager Imdylltra should be cleared as a second-line therapy for small cell lung cancer, says the #CHMP, which also backed new drugs from #Ferring, #Pharming, and #Proveca.

pharmaphorum.com/news/amgens-...